IL2 and renal cell carcinoma: Additionally, early clinical trials have been conducted to evaluate epigenetic therapies for RCC, either alone or in combination with other therapies including IFN-α2b, IL-2, anti-VEGF, TKIs, and mTOR inhibitors.